Institut Català de la Salut
[Delara R, Yang J, Magriña J, Butler K] Department of Obstetrics and Gynecology, Mayo Clinic, Phoenix, AZ. [Suárez-Salvador E] Department of Obstetrics and Gynecology, Mayo Clinic, Phoenix, AZ. Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vora S] Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ
Vall d'Hebron Barcelona Hospital Campus
2022-05-31T07:46:45Z
2022-05-31T07:46:45Z
2021-11-19
Intraoperative radiotherapy; Overall survival; Progression-free survival
Radioterapia intraoperatoria; Supervivencia global; Supervivencia libre de progresión
Radioteràpia intraoperatòria; Supervivència global; Supervivència lliure de progressió
Objective To report survival outcomes in patients with locally recurrent gynecologic cancers managed with curative-intent radical extirpation, perioperative external beam radiotherapy, and intraoperative radiotherapy (IORT). Patients and Methods We conducted a retrospective cohort analysis of 44 patients with locally recurrent gynecologic cancer treated at a single tertiary-care center (Mayo Clinic in Arizona) over a 15-year period (January 1, 2004, to July 31, 2019). This cohort included patients with uterine (n=21, 47.7%), ovarian (n=3, 6.8%), cervical (n=11, 25.0%), vaginal (n=2, 4.5%), vulvar (n=1, 2.3%), and unknown primary (n=6, 13.6%) cancer. Curative-intent radical extirpation included pelvic exenteration (n=13, 29.5%), laterally extended endopelvic resection (n=22, 50.0%), excision of para-aortic lymph node metastasis (n=8, 18.2%), and radical vaginectomy (n=1, 2.3%). Of the 44 patients in our cohort, 37 (84.1%) received IORT and 7 (15.9%) had intended to receive IORT but did not receive it. Results The median follow-up for the 44 patients was 12 months (range, 1 to 161 months). For patients who received IORT, the median progression-free survival (PFS) and overall survival (OS) were 13 and 21 months, respectively, and the 3-year cumulative incidence of central, locoregional, and distant recurrence was 27.0% (10 of 37), 40.5% (15 of 37), and 37.8% (14 of 37), respectively. Surgical margins were classified as negative (28 of 44, 63.6%), microscopic (11 of 44, 25.0%), or macroscopic (5 of 44, 11.4%). Negative, microscopic, and macroscopic surgical margins resulted in 3-year PFS of 51.8%, 20.5%, and 0%, respectively (P=.01) and 3-year OS of 62.9%, 20.0%, and 0%, respectively (P=.035). Progression-free survival (P=.69) and OS (P=.88) were not different between patients with negative surgical margins who received (n=21) and did not receive (n=7) IORT. Ten of 37 patients (27.0%) had development of grade 3 or higher toxicities, with 1 death due to sepsis. Conclusion Complete tumor resection at the time of curative-intent radical extirpation achieved higher rates of PFS and OS regardless of IORT administration.
Article
Published version
English
Aparell genital femení - Càncer - Cirurgia; Aparell genital femení - Càncer - Radioteràpia; Extirpació (Cirurgia); DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female; Other subheadings::Other subheadings::Other subheadings::/radiotherapy; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Local; Other subheadings::Other subheadings::Other subheadings::/surgery; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos; Otros calificadores::Otros calificadores::Otros calificadores::/radioterapia; ENFERMEDADES::neoplasias::procesos neoplásicos::recurrencia neoplásica local; Otros calificadores::Otros calificadores::Otros calificadores::/cirugía
Elsevier
Mayo Clinic Proceedings: Innovations, Quality & Outcomes;5(6)
https://doi.org/10.1016/j.mayocpiqo.2021.10.004
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3439]